Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages

  Takayama, Tetsuro ^a,b   Kanai, Takanaori ^a   Matsuoka, Katsuyoshi ^a   Okamoto, Susumu ^a   Sujino, Tomohisa ^a   Mikami, Yohei ^a   Hisamatsu, Tadakazu ^a   Yajima, Tomoharu ^a   Iwao, Yasushi ^c   Ogata, Haruhiko ^c   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytapheresis therapy; Inflammatory bowel disease; Long term prognosis; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; CYTAPHERESIS; DISEASE DURATION; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CYTAPHERESIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PATIENT READMISSION; PREDNISOLONE; PROGNOSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84872501293     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.05.005     Document Type: Article

References (22)

1. Talley N.J., Abreu M.T., Achkar J.P., Bernstein C.N., Dubinsky M.C., Hanauer S.B., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011, 106(Suppl. 1):S2-25.
2. Hoentjen F., Sakuraba A., Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep 2011, 13:475-485.
3. Blonski W., Buchner A.M., Lichtenstein G.R. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011, 27:346-357.
4. Sandborn W.J. State-of-the-art: immunosuppression and biologic therapy. Dig Dis 2010, 28:536-542.
5. Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur J Gastroenterol Hepatol 2008, 20:596-600.
6. Hibi T., Naganuma M., Kitahora T., Kinjyo F., Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003, 38:740-746.
7. Itzkowitz S.H., Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004, 126:1634-1648.
8. Saniabadi A.R., Hanai H., Fukunaga K., Sawada K., Shima C., Bjarnason I., et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007, 37:191-200.
9. Hanai H., Watanabe F., Takeuchi K., Iida T., Yamada M., Iwaoka Y., et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28-35.
10. Suzuki Y., Yoshimura N., Saniabadi A.R., Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004, 49:565-571.
11. Naganuma M., Funakoshi S., Sakuraba A., Takagi H., Inoue N., Ogata H., et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251-257.
12. Hanai H., Watanabe F., Yamada M., Sato Y., Takeuchi K., Iida T., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70:36-44.
13. Yamamoto T., Umegae S., Kitagawa T., Yasuda Y., Yamada Y., Takahashi D., et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 2004, 20:783-792.
14. Kanke K., Nakano M., Hiraishi H., Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004, 36:811-817.
15. Yamamoto T., Saniabadi A.R., Umegae S., Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006, 12:719-726.
16. Yamamoto T., Saniabadi A.R., Maruyama Y., Umegae S., Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007, 39:626-633.
17. Sakuraba A., Motoya S., Watanabe K., Nishishita M., Kanke K., Matsui T., et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009, 104:2990-2995.
18. Sands B.E., Sandborn W.J., Feagan B., Löfberg R., Hibi T., Wang T., et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409.
19. Hibi T., Sameshima Y., Sekiguchi Y., Hisatome Y., Maruyama F., Moriwaki K., et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009, 41:570-577.
20. Lindberg A., Eberhardson M., Karlsson M., Karlén P. Long-term follow-up with granulocyte and monocyte apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol 2010, 10:73-82.
21. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
22. Ogata H., Matsui T., Nakamura M., Iida M., Takazoe M., Suzuki Y., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.